iNK-CD64/16A cells: a promising approach for ADCC?

Research output: Contribution to journalEditorial

Abstract

Introduction: ADCC by natural killer (NK) cells is a key mechanism for several clinically successful tumor-targeting therapeutic antibodies. Most patients, however, have limited responses to this therapy and/or develop resistance. NK cells exclusively recognize IgG by their low-affinity FcγR CD16A. Areas covered: We describe in this editorial a novel recombinant FcγR that consists of CD64, the only high affinity IgG receptor, and the transmembrane and cytoplasmic regions of CD16A, a potent activating receptor. CD64/16A was expressed in engineered iPSCs that were differentiated into NK cells (referred to as iNK cells). Expert opinion: iNK-CD64/16A cells in combination with therapeutic antibodies provide a universal tumor antigen targeting approach and potential off-the-shelf cell therapy to treat various malignancies.

Original languageEnglish (US)
Pages (from-to)1229-1232
Number of pages4
JournalExpert Opinion on Biological Therapy
Volume19
Issue number12
DOIs
StatePublished - Dec 2 2019

Fingerprint

Antibody-Dependent Cell Cytotoxicity
Natural Killer Cells
IgG Receptors
Antibodies
Neoplasm Antigens
Tumors
Immunoglobulin G
Expert Testimony
Cell- and Tissue-Based Therapy
Neoplasms
Therapeutics

Keywords

  • Fc receptor
  • Natural killer cells
  • antibody
  • cancer
  • cell therapy
  • mAb therapy
  • stem cell

PubMed: MeSH publication types

  • Editorial

Cite this

iNK-CD64/16A cells : a promising approach for ADCC? / Walcheck, Bruce; Wu, Jianming.

In: Expert Opinion on Biological Therapy, Vol. 19, No. 12, 02.12.2019, p. 1229-1232.

Research output: Contribution to journalEditorial

@article{37e01deabf934fffbd9de34de62a729a,
title = "iNK-CD64/16A cells: a promising approach for ADCC?",
abstract = "Introduction: ADCC by natural killer (NK) cells is a key mechanism for several clinically successful tumor-targeting therapeutic antibodies. Most patients, however, have limited responses to this therapy and/or develop resistance. NK cells exclusively recognize IgG by their low-affinity FcγR CD16A. Areas covered: We describe in this editorial a novel recombinant FcγR that consists of CD64, the only high affinity IgG receptor, and the transmembrane and cytoplasmic regions of CD16A, a potent activating receptor. CD64/16A was expressed in engineered iPSCs that were differentiated into NK cells (referred to as iNK cells). Expert opinion: iNK-CD64/16A cells in combination with therapeutic antibodies provide a universal tumor antigen targeting approach and potential off-the-shelf cell therapy to treat various malignancies.",
keywords = "Fc receptor, Natural killer cells, antibody, cancer, cell therapy, mAb therapy, stem cell",
author = "Bruce Walcheck and Jianming Wu",
year = "2019",
month = "12",
day = "2",
doi = "10.1080/14712598.2019.1667974",
language = "English (US)",
volume = "19",
pages = "1229--1232",
journal = "Expert Opinion on Biological Therapy",
issn = "1471-2598",
publisher = "Elsevier BV",
number = "12",

}

TY - JOUR

T1 - iNK-CD64/16A cells

T2 - a promising approach for ADCC?

AU - Walcheck, Bruce

AU - Wu, Jianming

PY - 2019/12/2

Y1 - 2019/12/2

N2 - Introduction: ADCC by natural killer (NK) cells is a key mechanism for several clinically successful tumor-targeting therapeutic antibodies. Most patients, however, have limited responses to this therapy and/or develop resistance. NK cells exclusively recognize IgG by their low-affinity FcγR CD16A. Areas covered: We describe in this editorial a novel recombinant FcγR that consists of CD64, the only high affinity IgG receptor, and the transmembrane and cytoplasmic regions of CD16A, a potent activating receptor. CD64/16A was expressed in engineered iPSCs that were differentiated into NK cells (referred to as iNK cells). Expert opinion: iNK-CD64/16A cells in combination with therapeutic antibodies provide a universal tumor antigen targeting approach and potential off-the-shelf cell therapy to treat various malignancies.

AB - Introduction: ADCC by natural killer (NK) cells is a key mechanism for several clinically successful tumor-targeting therapeutic antibodies. Most patients, however, have limited responses to this therapy and/or develop resistance. NK cells exclusively recognize IgG by their low-affinity FcγR CD16A. Areas covered: We describe in this editorial a novel recombinant FcγR that consists of CD64, the only high affinity IgG receptor, and the transmembrane and cytoplasmic regions of CD16A, a potent activating receptor. CD64/16A was expressed in engineered iPSCs that were differentiated into NK cells (referred to as iNK cells). Expert opinion: iNK-CD64/16A cells in combination with therapeutic antibodies provide a universal tumor antigen targeting approach and potential off-the-shelf cell therapy to treat various malignancies.

KW - Fc receptor

KW - Natural killer cells

KW - antibody

KW - cancer

KW - cell therapy

KW - mAb therapy

KW - stem cell

UR - http://www.scopus.com/inward/record.url?scp=85073829633&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85073829633&partnerID=8YFLogxK

U2 - 10.1080/14712598.2019.1667974

DO - 10.1080/14712598.2019.1667974

M3 - Editorial

C2 - 31510805

AN - SCOPUS:85073829633

VL - 19

SP - 1229

EP - 1232

JO - Expert Opinion on Biological Therapy

JF - Expert Opinion on Biological Therapy

SN - 1471-2598

IS - 12

ER -